This Week in Cancer Discovery | GenomeWeb

This Week in Cancer Discovery

Premium

In Cancer Discovery, researchers in the US and Australia report that pre-existing MEK1 exon 3 mutations in V600E/KBRAF melanomas don't confer resistance to BRAF inhibitors. The team sequenced MEK1/2 exon 3 in 31 melanomas at disease diagnosis and at progression, and found that five of them carried concurrent somatic BRAF/MEK1 activating mutations. Three of those five patients showed objective responses to BRAF inhibitors, consistent with the overall response rate to these drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.